MeSH D055953 - microscopic polyangiitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Amgen | Rituximab | Riabni | 2020-12-17 | |||
| Biogen | Rituximab | Rituxan | 2002-02-19 | |||
| Celltrion | Rituximab | Blitzima | 2017-07-13 | |||
| Rituximab | Ritemvia | 2017-07-13 | ||||
| Rituximab | Rituzena (previously Tuxella) | 2017-07-13 | ||||
| Rituximab | Truxima | 2018-11-28 | ||||
| Genentech | Rituximab | Rituxan | 1997-11-26 | |||
| Rituximab, Hyaluronidase (human recombinant) | Rituxan Hycela | 2017-06-22 | ||||
| Pfizer | Rituximab | Ruxience | 2019-07-23 | $390 M | Y2023 | |
| Roche | Rituximab | MabThera | 1998-06-02 | |||
| Sandoz | Rituximab | Rixathon | 2017-06-15 | |||
| Rituximab | Riximyo | 2017-06-15 | ||||
| Vifor | Avacopan | Tavneos | 2022-01-11 |
Clinical Trials
Historical Success Rate
Phase 1
100%2/2
Phase 2
87%13/15
Phase 3
93%13/14
Approved: 3Overall Success rate: 80%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use